HSBC Holdings’s Marker Therapeutics MRKR Stock Holding History

HSBC Holdings’s Portfolio MRKR Stock Details MRKR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,669	Closed	-$16K	–	3404
2021 Q4	$16K	Sell	1,669 -103	-6%	-$1.37K	﹤0.01%	3232
2021 Q3	$30K	Sell	1,772 -85	-5%	-$1.74K	﹤0.01%	2947
2021 Q2	$54K	Buy	1,857 +2	+0.1%	+$53	﹤0.01%	2884
2021 Q1	$41K	Sell	1,855 -399	-18%	-$9.13K	﹤0.01%	2674
2020 Q4	$33K	Buy	2,254 +78	+4%	+$1.21K	﹤0.01%	3000
2020 Q3	$34K	Hold	2,176	–	–	﹤0.01%	2685
2020 Q2	$45K	Buy	+2,176	New	+$47.6K	﹤0.01%	2585

Other funds holding MRKR

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ACM

ACT Capital Management Wayne, Pennsylvania $153M AUM

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

AAM

AR Asset Management West Hollywood, California $517M AUM 18.31% 1-Year Est. Return

HSBC Holdings's MRKR Position: Q1 2022 in Review

HSBC Holdings sold out of Marker Therapeutics (MRKR) in Q1 2022, closing a stake of 1,669 shares — an estimated $16K sold.

HSBC Holdings first reported a position in MRKR in Q2 2020 and held it in 7 quarters. The position peaked at $54K in Q2 2021. 49 funds tracked by Wall St. Rank hold MRKR as of Q1 2022.

HSBC Holdings reported no remaining Marker Therapeutics position as of Q1 2022 after selling out during the quarter.
HSBC Holdings sold 1,669 Marker Therapeutics shares in Q1 2022, an estimated $16K.
HSBC Holdings first reported a position in Marker Therapeutics in Q2 2020 and held it in 7 quarters.
HSBC Holdings's Marker Therapeutics position peaked at $54K in Q2 2021.
49 funds tracked by Wall St. Rank held Marker Therapeutics as of Q1 2022.

Based on HSBC Holdings's 13F filing for Q1 2022, filed 16 May 2022.